Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

• Macrophage inflammatory protein 1α (MIP-1α), in rheumatoid synovitis, 1365
• Macrophage inflammatory protein 1β (MIP-1β), in rheumatoid synovitis, 1365
• Macrophage migration inhibitory factor (MIF), in rat adjuvant arthritis, 910
• Macrophages, in synovial tissue in RA, 663
• Magnetic resonance imaging (MRI)
  • cognitive defects in SLE and, 41
  • giant cell (temporal) arteritis and, 1702
  • of normal and osteoarthritic cartilage, 963
  • in spondylarthropathy of knee, 694
• Magnetic resonance spectroscopy (MRS), P-31, in fibromyalgia, 406
• Major histocompatibility complex (MHC)
  • in ankylosing spondylitis susceptibility, 588
  • in collagen-induced arthritis, 507
  • in genetic regulation of pristane-induced arthritis in mice, 2022
  • new non-MHC locus and collagen-induced arthritis, 2122
  • in RA, 498
• Major histocompatibility complex (MHC) class I-related chain gene A (MICA)
  • human cytomegalovirus associated with, 10
  • spondylarthropathies in HLA-B27 positive individuals and, 68
• Major histocompatibility complex (MHC) class I-related chain gene B (MICB)
  • Behcet's disease and, 68
  • spondylarthropathies in HLA-B27 positive individuals and, 68
• Major histocompatibility complex (MHC) I-Ag7, in primary SS, 150
• Malabsorption syndrome, and upper intestinal manometry in SSc, 1874
• Malignancies, and cyclosporine treatment risks in RA, 1930
• Mannose-binding lectin gene, SLE associated with promoter polymorphisms of, 1663
• Manometry, upper intestinal, in SSc, 1874
• Maternal antibodies, fetal heart block and, 2079
• Masked antibodies, heterogeneity of, 2089
• Matrix, replacement in vitro in articular cartilage, 263
• Matrix metalloproteinases (MMPs)
  • cathepsin expression in RA and OA and, 1378
  • COMP degradation by, 2143
  • paclitaxel inhibition of expression of, 869
  • in RA, 470, 1388
  • in synoviocytes and fibroblasts, 1748
  • transcription in synovial fibroblasts, and interleukin-4, 1398
• Median nerve compression, hand, 720
• Memory T cells, in SLE-associated glomerulonephritis, 335
• Meniscectomy, radiographic knee OA after, 687
• Metalloproteinases. See also Matrix metalloproteinases (MMPs); Tissue inhibitor of metalloproteinases 1 (TIMP-1)
  • nuclear factor [gk]B/p50 activation of distal metalloproteinase-1 promoter, 1987
  • oncostatin M in cartilage destruction and, 1760
  • paclitaxel inhibition of expression of, 869
  • in RA, 470, 1378
  • stromelysin in collagen-induced arthritis, 110
• Methotrexate (MTX)
  • -associated pneumonitis, 1327
  • in RA, biotechnology and, 1548
  • in childhood rheumatic diseases, 381
  • in RA, with cyclosporine therapy, 1703
  • in RA, immunoregulation of, 48
  • effect on monocytes, 2032
  • in RA, with multiple anti-tumor necrosis factor α infusions, 1552
  • in refractory myositis, 392
  • -treated rat adjuvant arthritis, 1407
• Methylprednisolone, in osteonecrosis, 1709, 1710
• Microsphere encapsulation of proteins, for joint therapy, 2185
• Misoprostol, and NSAIDs, 16
• Misoprostol Ulcer Complications Outcome Safety Assessment (MUCOSA) study, 16
• Mixed connective tissue disease (MCTD), as distinct disease entity, 768
• Monarticular arthritis, NO and interleukin-1 in, 634
• Monkey models, collagen-induced arthritis, 507
• Monoclonal antibody (MAb)
  • anti-Fas, in RA, 1251
  • anti-reshaping human interleukin-6 receptor, in RA, 2014
  • anti-Sm, cross-reactivity with ribosomal protein S10, 1040
  • anti-TNFα, in RA, 2205
  • human anticardiolipin, in mice, 1026
• Monocytes, MTX effect on, 2032
• Mortality
  • cyclosporine treatment risks in RA and, 1930
  • in psoriatic arthritis, 1103
• Mouse models
  • anti-interleukin-6 suppression of collagen-induced arthritis, 2117
  • antiphospholipid syndrome and ciprofloxacin, 224
  • anti-reshaping human interleukin-6 receptor treatment of RA in, 2014
  • arthritis and pneumonitis reduction by tumor necrosis factor receptor I in motheaten mice, 139
  • cartilage proteoglycan G1 domain in RA, inhibition by keratan sulfate, 1019
  • collagen, type X, in articular cartilage, 1287
  • collagen-induced arthritis and susceptibility and interleukin-1 receptor antagonist, 1798
  • control of collagen-induced arthritis in T cell receptor β-chain transgenic mice, 256
  • genetic regulation of pristane-induced arthritis in, 2022
  • human anticardiolipin monoclonal autoantibodies in, 1026
  • induction of apoptosis in RA synovial xenograft, 1251
  • interleukin-8 receptor binding chemokines in gout, 900
  • interleukin-1 regulation of matrix metalloproteinase-induced neoepitopes, in antigen-induced arthritis, 647
  • NOD-derived, of primary SS, 150
  • procollagen gene regulation in tight skin 2 mouse fibroblasts, 2132
  • proteoglycan-induced polyarteritis, 1007
  • RA treatment with anti-reshaping human interleukin-6 receptor monoclonal antibody, 2014
  • Ro 32-3555 in STR/ORT OA, 1639
  • role of NO and interleukin-1 in experimental arthritis, 634
  • snRNP autoantigens in SLE, 603
  • splenic B1a cells, expanded, in NZM2410 lupus-prone mice, 1652
  • stromelysin 1-deficient mice susceptibility to collagen-induced arthritis and cartilage destruction, 110
• Mucosal immunity, in rheumatic diseases, 572
• Multiple myeloma-associated amyloidosis, and giant cell (temporal) arteritis, 1312
• Multiple sclerosis, interferon-β in RA with, 754
• Muscle
  • and P-31 MRS in fibromyalgia, 406
  • quadriceps weakness as risk factor in knee, 1951
• Musculoskeletal disorders, prevalence in United States, 778
• Musculoskeletal manifestations, in polymyalgia rheumatica, 1221
• Mycobacterium tuberculosis, and Poncet's disease and papulonecrotic tuberculid in HIV, 1884
• Mycoplasma infection, in RA, 754, 756
• Myelodysplastic syndromes, and alkylating drug therapy in rheumatic disease, 1493
• Myopathy
  • idiopathic inflammatory, 400, 710
• Myositis
  • anti-transfer RNA antibodies in, 1625
  • anti-transfer RNAHis antibodies in, 1428
  • cytotoxic treatments for refractory, 392